Skip to content
Trial Eligibility
Menu

F 18 T807 Tau PET Imaging of Alzheimer's Disease

NCT02414347

This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

A single-center, open-label baseline controlled imaging study designed to assess whether brain tau fibril uptake of flortaucipir as measured by PET correlates with cognitive status of individuals with and without brain tau fibrils.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Alzheimer Disease

Eligibility basics and study details

Study type
Observational
Phase
Not applicable
Ages
18 years and older
Sex
All
Healthy volunteers
Not accepted
Sponsor
Tammie L. S. Benzinger, MD, PhD
Last updated on ClinicalTrials.gov
June 8, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

Missouri · 1

  • Washington University School of Medicine · St Louis, MO

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.